Clinical trials: Poor Graft Function
Graft-versus-host Disease, Poor Graft Function
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD.
- Conditions
- Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
- Trial name
- NCT00603330
- Testing
- Mesenchymal stem cells
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Liege
Poor Graft Function, Stem Cell Transplantation
G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation
Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The pathogenesis fo PGF was poorly understood.
- Conditions
- Poor Graft Function, Stem Cell Transplantation, Graft Versus Host Disease
- Trial name
- NCT01857336
- Testing
- infusion of G-CSF mobilized peripheral harvest
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Graft Failure, Poor Graft Function
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft…
- Trial name
- NCT06569082
- Testing
- CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
MSC
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective approach for treating both benign and malignant blood disorders.
- Trial name
- NCT06171906
- Testing
- mesenchymal stromal cells
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- ShiCang Yu
Blood And Marrow Transplantation
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
- Trial name
- NCT02438904
- Testing
- CD34 Positive Stem Cell Infusion, Miltenyi device
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Stem Cell Transplantation, Hematopoietic, Mesenchymal Stem Cells
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Mesenchymal Stem Cells, Poor Graft Function, Hematological Diseases
- Trial name
- NCT01763086
- Testing
- Mesenchymal stem cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy.
- Trial name
- NCT02350777
- Testing
- Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Poor Graft Function, Aplastic Anemia Idiopathic
REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2
Allogeneic stem cell transplantation involves the transplanting of donor blood stem cells into a recipient, this is performed mainly for the treatment of blood cancers.
- Trial name
- RESELECT2 (NCT06607367)
- Testing
- Ruxolitinib (JAKAVI®), Eltrombopag (Revolade®)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melbourne Health
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Terminal Liver Disease, Ischemia Reperfusion Injury
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
Utilisation of extended criteria donors due to critical organ shortage contributes to increased ischemia reperfusion injury as well as mortality following liver transplantation.
- Conditions
- Terminal Liver Disease, Ischemia Reperfusion Injury, Graft Dysfunction, Graft Failure
- Trial name
- TOP (NCT01564095)
- Testing
- Tacrolimus
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Kidney Transplantation, Acute Kidney Tubular Necrosis
Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.
This study is designed to investigate whether allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) can promote function recovery in patients with poor early graft function after kidney transplantation from Chinese…
- Trial name
- NCT02563366
- Testing
- BM-MSCs, Saline
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with Granulocyte Colony-Stimulating Factor (G-CSF) mobilized…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Hematological Diseases
- Trial name
- NCT02083718
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Poor Graft Function
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks…
- Trial name
- ELTION (NCT03718533)
- Testing
- Eltrombopag
- Where
- 7 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Delayed Platelet Engraftment, Hematological Diseases
- Trial name
- NCT02240992
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Poor Graft Function
Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the efficacy and safety for secondary poor graft function (PGF) post allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the hematologic response rate.
- Trial name
- NCT03437603
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Poor Graft Function
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
This study is conducted in a prospective, single-center clinical design and is divided into two stages: dose escalation and dose extension.
- Trial name
- NCT06792682
- Testing
- Dose escalation, Dose extension
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Coronary Artery Bypass Grafting, Left Ventricular Dysfonction
Preoperative Levosimendan in CABG Patients With Poor LV Function
The investigators want to test the hypothesis that an infusion of levosimendan started prior to CABG surgery can reduce incidence and severity of low cardiac output syndrome in patients with poor LV function (EF 40% or less).
- Trial name
- LICORN (NCT02184819)
- Testing
- levosimendan
- Where
- France
- Volunteers
- 335 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemia Reperfusion Injury
YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal…
- Trial name
- YSPSL (NCT00876902)
- Testing
- recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Y's Therapeutics, Inc.
Poor Graft Function
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT
This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
- Trial name
- NCT05669079
- Testing
- decitabine, umbilical cord blood, Granulocyte-colony stimulating factor
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Graft Failure
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
Poor graft function (PGF) after allogeneic hematopoietic cell transplantation (allo-HCT) is a misunderstood complication associated with poor outcome and limited therapeutic options.
- Trial name
- REGALIA (NCT03948529)
- Testing
- eltrombopag
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille